PENNSAID Drug Insight

“PENNSAID Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about PENNSAID for chronic pain in the seven major markets. A detailed picture of the PENNSAID for chronic pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the PENNSAID for chronic pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PENNSAID market forecast analysis for chronic pain in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic pain.

Drug Summary

PENNSAID topical solution is a clear, colorless, faintly pink-orange solution for topical application. It contains 1.5% w/w diclofenac sodium, a benzeneacetic acid derivative that is an NSAID, designated chemically as 2-[(2,6-dichlorophenyl) amino] benzeneacetic acid, monosodium salt. The molecular weight is 318.14 and molecular formula is C14H10Cl2NNaO2.

Each 1 mL of solution contains 16.05 mg of diclofenac sodium. In addition, PENNSAID topical solution contains inactive ingredients: dimethyl sulfoxide USP (DMSO, 45.5% w/w), propylene glycol, alcohol, glycerin, and purified water.

Mechanism of action

The mechanism of action of diclofenac is similar to other NSAIDs. Diclofenac inhibits the enzyme Cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes, and prostacyclin. The mechanism of reduced synthesis of these compounds resulting in therapeutic efficacy is not completely understood.

Dosage form and strength

1.5% w/w topical solution.

Dosage and administration

To relieve the signs and symptoms of osteoarthritis of the knee(s), the recommended dose is 40 drops per knee, four times daily. Apply PENNSAID topical solution to clean, dry skin. To avoid spillage, dispense PENNSAID 10 drops at a time either directly onto the knee, first into the hand, and then onto the knee. Spread PENNSAID topical solution evenly around the front, back, and sides of the knee. Repeat this procedure until 40 drops have been applied and the knee is completely covered with solution.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the PENNSAID description, mechanism of action, dosage and administration, research and development activities in chronic pain.
• Elaborated details on PENNSAID regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PENNSAID research and development activities in chronic pain across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PENNSAID.
• The report contains forecasted sales of for chronic pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic pain.
• The report also features the SWOT analysis with analyst views for PENNSAID in chronic pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PENNSAID Analytical Perspective by DelveInsight

• In-depth PENNSAID Market Assessment

This report provides a detailed market assessment of PENNSAID for chronic pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• PENNSAID Clinical Assessment

The report provides the clinical trials information of PENNSAID for chronic pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PENNSAID dominance.
• Other emerging products for chronic pain are expected to give tough market competition to PENNSAID and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PENNSAID in chronic pain.
• Our in-depth analysis of the forecasted sales data of PENNSAID from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PENNSAID in chronic pain

Key Questions

• What is the product type, route of administration and mechanism of action of PENNSAID?
• What is the clinical trial status of the study related to PENNSAID in chronic pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PENNSAID development?
• What are the key designations that have been granted to PENNSAID for chronic pain?
• What is the forecasted market scenario of PENNSAID for chronic pain?
• What are the forecasted sales of PENNSAID in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to PENNSAID for chronic pain?
• Which are the late-stage emerging therapies under development for the treatment of chronic pain?